![]() ![]() Now, with the approval of idarucizumab (Praxbind Boehringer Ingelheim) more than a year ago and the ongoing development of reversal agents for the other NOACs, that hesitancy will go away, he said. The lack of effective ways to neutralize the anticoagulant effects of the NOACs “most definitely” has discouraged some physicians and patients from using the agents, Tomaselli added. Moreover, said Tomaselli, who was one of the moderators of the session at which Pollack presented the findings, “I think it may engender greater use of dabigatran over other NOACs until the others have a reversal agent that’s available.” “I think idarucizumab really does pretty safely, pretty effectively, pretty quickly reverse anticoagulation.” ![]() No safety concerns were identified.Ĭommenting on the study for TCTMD, former AHA president Gordon Tomaselli, MD (Johns Hopkins Medicine, Baltimore, MD), said the results-consistent with a preliminary report -were reassuring. The effect of the agent, a humanized monoclonal antibody fragment that selectively binds to dabigatran (Pradaxa Boehringer Ingelheim), was seen within minutes of initial administration and was sustained for at least 4 hours, Charles Pollack Jr., MD (Thomas Jefferson University, Philadelphia, PA), said during his presentation at the American Heart Association (AHA) Scientific Sessions 2016 here.Īlthough low levels of dabigatran reappeared within 24 hours in some patients, there were no clinical consequences, he reported. NEW ORLEANS, LA-Administration of idarucizumab induces rapid and complete reversal of the anticoagulant effects of dabigatran, both in patients presenting with uncontrolled bleeding and in those requiring emergency surgery or other interventions, according to updated results from the RE-VERSE AD study.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |